Drug developers need technologies to accelerate their drug development. Yet, they are telling us they currently have very low visibility on companies providing solutions that will enhance their immunooncology development.
If your business strategy is to target the immunooncology space, ICI Europe Summit is a critical step in realising your success. This meeting offers you unrivalled opportunities to showcase your solutions, generate new business leads, and source opportunities for partnerships.
Meet the decision-makers from pharma and biotech who are committed to speeding up the development of their ICI drugs. Whether you provide the latest humanised tumour models; technology to discover checkpoint pathways; clinical monitoring tools or a combination therapy, partnering with us will secure your market share in this commercially booming market.
Act now to stay ahead of the curve and maximise the wealth of opportunity on offer.
Who Should Sponsor?
- CROs with knowledge in running complex immunotherapy trials
- Tumour models providers to share more predictive tools for translational research
- Companies with complimentary immune boosting drugs to build strong business cases for rational combination therapies
- Diagnostic developers working on new biomarker tests to help clinical patient selection strategies
- Target discovery platforms to identify new novel pathways for the next generation of drugs
We can ensure your company stands out in this competitive field.
It’s worth us having a conversation early so that we can tailor a bespoke package for your needs. Simply email email@example.com to find out more.